- Q3 net sales (-1% cc[2] and USD) broadly in line with prior year due to strong performance of Growth Products
- Gilenya (USD 790 million, +15% cc) continued double-digit growth
- Cosentyx (USD 301 million) on track for blockbuster status in first full year after approval
- Oncology growth drivers including Tafinlar + Mekinist (USD 172 million, +29% cc), Promacta/Revolade (USD 168 million, +44% cc) and Jakavi (USD 149 million, +47% cc)
- Sandoz Biopharmaceuticals[1] (USD 262 million, +41% cc) …
- Despite significant advances made by modern medicine, universal access to healthcare is still arguably the single largest unmet medical need
- Sandoz “HACk” – Healthcare Access Challenge – is a competition seeking young people with innovative ideas to “reimagine” access to healthcare
- Sandoz HACk is partnering with OpenIDEO – a global community that drives collaboration, innovation and impact around the world’s toughest problems
Holzkirchen, September 28, 2016 – Sandoz, the Novartis generic and biosimilar …
- Sandoz, a Novartis division, the pioneer and global leader in biosimilars acquired the rights from Pfizer for the development, commercialization and manufacture of PF-06438179 in the 28 countries that form the European Economic Area (EEA)* in February 2016 where it is known as GP1111.
- The confirmatory study (REFLECTIONS B537-02), evaluating the efficacy, safety and immunogenicity of PF-06438179 (biosimilar infliximab) to reference product Remicade® (infliximab), met its primary endpoint.
- Results demonstrate equivalent efficacy as measured by the American College of …
- New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®.
- Study highlights importance of improving treatment “persistence” over time for long-term respiratory diseases.
- Analysis, published in leading medical journal, is largest European Real-World Evidence study ever conducted in asthma and COPD.
[1] Seretide® and Diskus® are registered trademarks owned by Glaxo Group Ltd.
Holzkirchen, August 31, 2016 – New data just …
- New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®.
- Study highlights importance of improving treatment “persistence” over time for long-term respiratory diseases.
- Analysis, published in leading medical journal, is largest European Real-World Evidence study ever conducted in asthma and COPD.
[1] Seretide® and Diskus® are registered trademarks owned by Glaxo Group Ltd.
Holzkirchen, August 31, 2016 – New data just …
- Erelzi is approved for all indications included in the reference product’s label
- Erelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine
- Erelzi is the second biosimilar from Sandoz to receive FDA approval in the US, building upon established global leadership in biosimilars
Holzkirchen, August 30, 2016 – Sandoz, a Novartis division and the global leader in biosimilars, announced today that the US Food and Drug Administration (FDA …
- Erelzi is approved for all indications included in the reference product’s label
- Erelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine
- Erelzi is the second biosimilar from Sandoz to receive FDA approval in the US, building upon established global leadership in biosimilars
Holzkirchen, August 30, 2016 – Sandoz, a Novartis division and the global leader in biosimilars, announced today that the US Food and Drug Administration (FDA …
- First-of-a-kind service for healthcare professionals will offer access to latest news from leading international transplantation congress.
- Transplant TODAY online service will be launched at this month’s International Congress of the Transplantation Society (TTS).
- Sandoz, the leading global supplier of generic transplantation medicines, collaborates with international experts to offer this service.
Holzkirchen, August 9, 2016 – Sandoz today announces the launch of a novel online medical education platform, Transplant TODAY, offering access …
- First-of-a-kind service for healthcare professionals will offer access to latest news from leading international transplantation congress.
- Transplant TODAY online service will be launched at this month’s International Congress of the Transplantation Society (TTS).
- Sandoz, the leading global supplier of generic transplantation medicines, collaborates with international experts to offer this service.
Holzkirchen, August 9, 2016 – Sandoz today announces the launch of a novel online medical education platform, Transplant TODAY, offering access …
- Q2 net sales were flat (0% cc[1]) as Growth Products[2] offset Gleevec generic impact
- Gilenya (USD 811 million, +17% cc) continued to grow double-digit mainly due to volume growth
- Cosentyx (USD 260 million) grew strongly driven by its three approved indications
- Core[1] operating income declined (-4% cc) due to generic erosion and growth investments
- Core M&S expenses up 0.8 percentage points (cc) to 24.6% of sales, mainly driven by Cosentyx, Entresto and Alcon …
Follow us on Facebook
ADDRESS – ZIMBABWE
Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe
ADDRESS – ZAMBIA
Plot 43504
Apex Chalala
Off Kasama Road
Lusaka Zambia